Saudi practical guidelines on biologic treatment of psoriasis

Abstract

The current treatment of psoriasis patients with biologic agents in the Kingdom of Saudi Arabia (KSA) is mainly based on clinical experience. Although there are published international guidelines for treatment with biologics, such as the European S3 guidelines (a joint project of the European Dermatology Forum, the European Academy of Dermatology and Venereology, and the International Psoriasis Council), many nations have found it beneficial to develop country-based guidelines that incorporate specific regional aspects of therapy (legal and practical). With the expanded role of biologic agents in the treatment of psoriasis in Saudi Arabia, a need for local Saudi guidelines has become evident. Here we present a practical approach to the evidence-based clinical administration of biologics for professionals who treat patients with psoriasis.

• Adalimumab
• etanercept
• infliximab
• psoriatic arthritis
• ustekinumab

Acknowledgements

We would like to thank Prof. Dr. Diamant Thaci for help in reviewing this manuscript and constructive suggestions in preparing this guideline.

Declaration of interest

The authors report no conflict of interest.